Compare Enveric Biosciences Inc (ENVB) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vale SA — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Vale SA trades at $14.27 (market cap $61.19B). The key difference: Vale SA is far larger — about 11501.9× Enveric Biosciences Inc's market cap, and Vale SA pays a 8.58% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | VALE | |
|---|---|---|
Market Cap | $5.32M | $61.19B |
Sector | Health | Basic Materials |
52-Week High | $17.40 | $17.82 |
52-Week Low | $1.28 | $9.53 |
Enterprise Value | $408.82K | $78.11B |
Dividend Yield | — | 8.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
VALE trades at $14.59, up 2.89% in the last session, with a bearish technical signal and mixed earnings history. Recent quarters show volatility with one beat and two misses. The company maintains solid cash flow from operations at $8.8B in 2025, though net income margin has declined to 7.21%. News highlights include a $2.6B decarbonization investment plan (Reuters, 2026-06-15) and governance tensions with a board rejecting a chairman removal push (GuruFocus, 2026-06-22).
The outlook is cautious with analyst consensus at Buy (40.54%) but near-term risks from earnings volatility and debt levels. Upside exists if the company meets Q2 2026 EPS expectations of $0.46, supported by robust metals demand per CEO comments (Bloomberg, 2026-06-09). Key risks include profit margin pressure and geopolitical impacts on operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
